Inify Laboratories announces CQC registration and full operational launch of its state-of-the-art UK histopathology laboratory

27 May 2026 10:16 CEST

South Oxfordshire, UK - May 27, 2026 - Inify Laboratories, a unique laboratory
service that provides diagnostics within pathology, today announced that it has
successfully achieved registration with the Care Quality Commission (CQC),
marking a major milestone in the company's UK expansion and confirming that the
laboratory is now fully operational and open to receive clinical histopathology
samples from healthcare providers across the United Kingdom.

Located in South Oxfordshire, the newly established laboratory has been purpose
built to support high-quality, histopathology diagnostics combining advanced
laboratory infrastructure with digital pathology workflows, designed to
streamline clinical pathways from diagnostics to treatment.

The CQC registration enables Inify Laboratories Ltd to provide regulated
diagnostic and screening services in England and represents a significant step
in bringing the wider Inify Group's expertise in digital pathology and pathway
thinking to the UK market.

The new facility has been designed to deliver an optimised working environment
for specialist pathology services, with investment in modern equipment, digital
development and scalable operational processes to support future growth and
innovation.

"Achieving CQC registration is a significant milestone for Inify Laboratories
Ltd and an important validation of the quality systems, governance and
operational standards we have built into the laboratory from the outset", say's
Kate Bucknall, Managing Director UK, Inify Laboratories Ltd.  "We are extremely
proud to have established a fully operational, state-of-the-art histopathology
laboratory in the UK that is now ready to support healthcare providers with high
-quality diagnostic services".

From the beginning, the company's focus has been on creating a laboratory
environment that combines operational excellence with digital innovation,
enabling   delivery of its efficient, reliable and scalable pathology services.
This while maintaining the highest diagnostic quality, thus improving the
standards of patient care.

"This milestone is also a testament to the hard work and dedication of the
entire UK team and colleagues across the wider Inify Group. We are excited to
begin accepting clinical samples and to build long-term partnerships with
healthcare providers across the UK". Kate Bucknall continues.

Fredrik Palm, CEO of Inify Group and Director of Inify Laboratories Ltd, added
"The CQC registration and operational launch of the UK laboratory represent an
important strategic step for the Inify Group and further strengthen our position
in digital pathology and cancer diagnostics. We are delighted to see the UK
business now fully operational and ready to support customers with diagnostic
services."

For further information, please contact Kate Bucknall, Managing Director Inify
Laboratories Ltd, kate.bucknall@inify.com, or visit https://www.inify.com

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)

More information:
Access the news on Oslo Bors NewsWeb site

674567_Inify_Laboratories_CQC_registration.pdf